drugset / Trial / NCT06002555
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
RandomizedParallel-groupOpen-labelOther
Summary
This trial compares the relative bioavailability of apraglutide in dual-chamber syringes (DCS) versus the reference formulation apraglutide in vials.
Timeline
- Start
- 2023-05-23
- Primary completion
- 2023-09-22
- Completion
- 2023-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apraglutide | Peptide | 2.5 mg | Subcutaneous |
| Subject | Apraglutide | Peptide | 5 mg | Subcutaneous |
Indications
No indication recorded.